FEMASYS INC
No SEC Form 4 filings for $FEMY in the last 30 days.
Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.
Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.
Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning FEMY (FEMASYS INC). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent FEMY coverage spans financial news, corporate actions and market movers.
The dilutive financing and warrant overhang likely pressure near-term valuation and sentiment, with potential upside only if warrant exercise materializes.
The financing strengthens near-term liquidity but introduces dilution risk and milestone overhang tied to future performance.
Compliance restoration reduces delisting risk, supporting the equity story, while the Q1 turnaround provides incremental fundamental support.
Routine shareholder-meeting outcomes; no new operating guidance, financing, or legal/regulatory action disclosed.
Near-term trading is driven by low-price, high-volatility conditions plus mixed sell-side target updates; fundamentals remain weak per the cited May 8 results.
alphai scores every news story that mentions FEMY with an AI model for sentiment and relevance, and aggregates insider trades from FEMASYS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.
3 min readFemasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.
4 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min readFEMASYS INC (FEMY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001339005 0001339005 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2026
2 min readFemasys Inc. (NASDAQ:FEMY) shares fell 2.4% to $0.3779 on Monday, after trading between $0.3610 and $0.3779; volume was 837,438 shares, down 59% vs. average. Analysts: Lake Street Capital set a $1.50 buy target; others cut to sell. MarketBeat cites a $5.33 average target. In May 8 earnings, EPS was $0.00 vs. -$0.07 expected; revenue was $0.42M vs. $0.77M.
3 min readFemasys Inc. filed an 8-K to present an updated corporate presentation detailing its women's reproductive health portfolio and growth strategy. The presentation focuses on FemaSeed for in-office fertility treatment and FemBloc, a non-surgical permanent birth control undergoing a U.S. pivotal trial. The company highlights the significant unmet market needs in fertility and contraception, presenting clinical data for both products and outlining their commercialization plans and economic benefits for OB/GYN practices.
3 min readFemasys Inc. reported a Q1 2026 net income of $846,100, reversing a prior-year net loss, primarily due to non-cash fair value adjustments on conversion option and warrant liabilities. The company increased sales by 24.5% to $424,889 and significantly reduced its operating loss, while cash and cash equivalents of $5.4 million are expected to fund operations into Q3 2026. Femasys is also advancing commercialization of its FemaSeed product and has initiated patient enrollment for the FemBloc FINALE pivotal clinical trial.
2 min readFemasys (FEMY) has amended its Senior Secured Convertible Notes and related warrants through an Omnibus Amendment and Consent Agreement with holders. The key change removes the Share Combination Event Adjustment, effective December 31, 2025. In consideration for this amendment, Femasys will issue over 16 million new Series D-1 Warrants with an exercise price of $0.58.
2 min readPharmaCyte Biotech, Inc. has reported a beneficial ownership of 4,932,825 shares of Femasys Inc. common stock, which represents 7.87% of the class. This stake includes 695,537 currently held shares and Series A warrants exercisable for an additional 4,237,288 shares, subject to a 19.99% beneficial ownership limitation. The filing is an amendment to a previous Schedule 13D, noting that Joshua Silverman resigned from Femasys' Board of Directors, and PharmaCyte Biotech no longer holds securities with the purpose of changing or influencing control of the issuer.
2 min readFemasys Inc. announced inducement grants of options to purchase 185,000 shares of common stock to two new non-executive employees hired in February 2026. These grants, with exercise prices tied to the closing price on their employment dates, were approved by the Compensation Committee as a material inducement for employment and will vest over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4).
2 min read
